Cargando…
Modulating epigenetic modifications for cancer therapy (Review)
Cancer is a global public health concern. Alterations in epigenetic processes are among the earliest genomic aberrations occurring during cancer development and are closely related to progression. Unlike genetic mutations, aberrations in epigenetic processes are reversible, which opens the possibili...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942256/ https://www.ncbi.nlm.nih.gov/pubmed/36799181 http://dx.doi.org/10.3892/or.2023.8496 |
_version_ | 1784891459353182208 |
---|---|
author | Castro-Muñoz, Leonardo Josué Vázquez Ulloa, Elenaé Sahlgren, Cecilia Lizano, Marcela De La Cruz-Hernández, Erick Contreras-Paredes, Adriana |
author_facet | Castro-Muñoz, Leonardo Josué Vázquez Ulloa, Elenaé Sahlgren, Cecilia Lizano, Marcela De La Cruz-Hernández, Erick Contreras-Paredes, Adriana |
author_sort | Castro-Muñoz, Leonardo Josué |
collection | PubMed |
description | Cancer is a global public health concern. Alterations in epigenetic processes are among the earliest genomic aberrations occurring during cancer development and are closely related to progression. Unlike genetic mutations, aberrations in epigenetic processes are reversible, which opens the possibility for novel pharmacological treatments. Non-coding RNAs (ncRNAs) represent an essential epigenetic mechanism, and emerging evidence links ncRNAs to carcinogenesis. Epigenetic drugs (epidrugs) are a group of promising target therapies for cancer treatment acting as coadjuvants to reverse drug resistance in cancer. The present review describes central epigenetic aberrations during malignant transformation and explains how epidrugs target DNA methylation, histone modifications and ncRNAs. Furthermore, clinical trials focused on evaluating the effect of these epidrugs alone or in combination with other anticancer therapies and other ncRNA-based therapies are discussed. The use of epidrugs promises to be an effective tool for reversing drug resistance in some patients with cancer. |
format | Online Article Text |
id | pubmed-9942256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-99422562023-02-22 Modulating epigenetic modifications for cancer therapy (Review) Castro-Muñoz, Leonardo Josué Vázquez Ulloa, Elenaé Sahlgren, Cecilia Lizano, Marcela De La Cruz-Hernández, Erick Contreras-Paredes, Adriana Oncol Rep Review Cancer is a global public health concern. Alterations in epigenetic processes are among the earliest genomic aberrations occurring during cancer development and are closely related to progression. Unlike genetic mutations, aberrations in epigenetic processes are reversible, which opens the possibility for novel pharmacological treatments. Non-coding RNAs (ncRNAs) represent an essential epigenetic mechanism, and emerging evidence links ncRNAs to carcinogenesis. Epigenetic drugs (epidrugs) are a group of promising target therapies for cancer treatment acting as coadjuvants to reverse drug resistance in cancer. The present review describes central epigenetic aberrations during malignant transformation and explains how epidrugs target DNA methylation, histone modifications and ncRNAs. Furthermore, clinical trials focused on evaluating the effect of these epidrugs alone or in combination with other anticancer therapies and other ncRNA-based therapies are discussed. The use of epidrugs promises to be an effective tool for reversing drug resistance in some patients with cancer. D.A. Spandidos 2023-02-10 /pmc/articles/PMC9942256/ /pubmed/36799181 http://dx.doi.org/10.3892/or.2023.8496 Text en Copyright: © Castro-Muñoz et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Review Castro-Muñoz, Leonardo Josué Vázquez Ulloa, Elenaé Sahlgren, Cecilia Lizano, Marcela De La Cruz-Hernández, Erick Contreras-Paredes, Adriana Modulating epigenetic modifications for cancer therapy (Review) |
title | Modulating epigenetic modifications for cancer therapy (Review) |
title_full | Modulating epigenetic modifications for cancer therapy (Review) |
title_fullStr | Modulating epigenetic modifications for cancer therapy (Review) |
title_full_unstemmed | Modulating epigenetic modifications for cancer therapy (Review) |
title_short | Modulating epigenetic modifications for cancer therapy (Review) |
title_sort | modulating epigenetic modifications for cancer therapy (review) |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942256/ https://www.ncbi.nlm.nih.gov/pubmed/36799181 http://dx.doi.org/10.3892/or.2023.8496 |
work_keys_str_mv | AT castromunozleonardojosue modulatingepigeneticmodificationsforcancertherapyreview AT vazquezulloaelenae modulatingepigeneticmodificationsforcancertherapyreview AT sahlgrencecilia modulatingepigeneticmodificationsforcancertherapyreview AT lizanomarcela modulatingepigeneticmodificationsforcancertherapyreview AT delacruzhernandezerick modulatingepigeneticmodificationsforcancertherapyreview AT contrerasparedesadriana modulatingepigeneticmodificationsforcancertherapyreview |